Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.6 (
RNA polymerase
)
34,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The present study describes the separation and purification of a reverse transciptiase from an orbital tumor of a patient with acute myelomonocytic
leukemia
. Specific reaction conditions with respect to ionic requirements and template-primers are reported. The purified enzyme was able to transcribe (rA)n . (dT)12, (rC)n . (dG)12, (OMeC)n . (dg)12 and the 70 S RNA from R(Mu)LV. Serological studies that the reverase
transcriptase
is antigenically related to reverse transcriptase from the type C woolly monkey virus-gibbon ape
leukemia
virus group.
...
PMID:RNA-dependent DNA polymerase activity in ocular granulocytic sarcoma associated to acute myelomonocytic leukemia in Turkish children. Biochemical and immunological characterization of the enzyme. 615 28
Interferon treatment of mouse cells chronically infected with Moloney
leukemia
virus (3T3/MLV) resulted in 97 per cent inhibition of infective virus release. The intracellular localization and distribution of virus reverse-
transcriptase
and group specific (gs) antigen were determined in interferon treated and control cells. Cytoplasm of infected cells was fractionated by isopycnic centrifugation on discontinuous sucrose gradients. Fractions were analysed for their chemical composition and characterized by the activity of membranal marker enzymes. The association and levels of viral antigens were determined in each fraction. Fractions enriched with 5' nucleotidase, specific enzyme marker for plasma membrane, were also enriched with viral proteins. In interferon treated cells, intracellular accumulation of viral proteins was specifically localized in the plasma membrane. Threefold increase in reverse-
transcriptase
level was the maximal accumulation found in purified plasma membranes. Intracellular enzyme levels in interferon treated cells were in accordance with the amount of cell associated infective virus particles. The small accumulation of viral proteins and infective virus particles was not sufficient to account for the great reduction in virus yield observed in the supernatants of the interferon treated cells. A possible role for interferon in modification of plasma membrane associated with virus assembly is postulated.
...
PMID:Localization of reverse-transcriptase in interferon-treated mouse cells chronically infected with Moloney leukemia virus. 615 72
Polyspermine-ribonuclease (Mr approximately 17 000) and the enzyme
transcriptase
from Rauscher-
leukaemia
virus (Mr approximately 70 000) form a complex Mr approx. 160 000) such that the molar ratio of polyspermine-ribonuclease to reverse transcriptase is 5:1. The most favourable condition for complex-formation is in a solution consisting of 0.01 M-Tris/HCl buffer, pH 7.5, 0.25 M-KCl and 1 mM-Mn2+ at 37 degrees C. The association of the two enzymes retains full RNAase activity, but reverse-
transcriptase
activity is completely inhibited when ribonuclease-sensitive polymers such as (dG)12 x (rC)n or viral 70S RNA are used as primer templates.
...
PMID:Complexing reverse transcriptase with polyspermine-ribonuclease. 616 6
Macbecin I showed marked antitumor activity against intraperitoneally (ip) inoculated
leukemia
P388, melanoma B16, and Ehrlich carcinoma in mice on ip administration. The maximum effect measured in terms of ILS% (increase of life span) was 97 at a daily dose level of 10 mg/kg for
leukemia
P388, 103 at 5 mg/kg for melanoma B16, and 206 at 10 mg/kg for Ehrlich carcinoma. The effect of macbecin I on
leukemia
L1210 was slight (39 ILS%) and no activity was observed against
leukemia
L5178Y or P388/P-3 (a line of P388 resistant to ansamitocin P-3), or MOPC-104E myloma. Three to six hours after administration of 0.5 mg/kg or more of macbecin I to mice bearing ascites
leukemia
P388 cells, typical karyorrhexis followed by cytolysis in P388 cells was observed. Cytocidal changes induced by macbecin I were also observed in cells which were temporarily prevented from entering mitosis by treatment with known antitumor agents such as 5-fluorouracil, cyclophosphamide, and neocarzinostatin, whereas such cytolysis was not observed in cells which were arrested in metaphase by treatment with ansamitocin P-3. Cytotoxicity of macbecin I to cultured KB cells was observed at doses of 10(-1) micrograms/ml and more. Reverse
transcriptase
and terminal deoxynucleotidyl transferase activities were not inhibited by macbecin I.
...
PMID:Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I. 618 64
The effect of glutaurine (gamma-L-glutamyl-taurine, Litoralon) on the take and development of hepatoma and acute
leukaemia
induced by MC29/L avian oncorna-virus has been investigated in turkey poults. Glutaurine significantly decreased the incidence of hepatoma, but had no significant effect on the lethality of MC29/L infected birds. The number of primitive myeloid cells was lower in the peripheral blood of glutaurine treated birds than in the untreated controls. Reverse
transcriptase
determinations in turkey fibroblast cell cultures indicated that glutaurine delays MC29/L virus expression.
...
PMID:Effect of glutaurine on liver tumour development and acute leukaemia induced by MC29 virus in turkey poults. 619 56
A 200-fold inhibition in the titer of infectious vesicular stomatitis virus (VSV) was produced in cultures of Ly cells treated with 30 reference units of interferon per milliliter. Virus particle production, as measured by VSV particle-associated
transcriptase
, or nucleocapsid protein was inhibited by a maximum of tenfold. The glycoprotein and membrane protein content was reduced in VSV derived from interferon-treated cells. Thus interferon-treated cells may have produced VSV particles with low infectivity, which may be related to the reduced amount of glycoprotein incorporated into such particles. These findings resemble those reported in interferon-treated cells infected with murine
leukemia
viruses.
...
PMID:Selective inhibition of glycoprotein and membrane protein of vesicular stomatitis virus from interferon-treated cells. 624 16
Some unintegrated and all integrated forms of murine
leukemia
viral DNA contain long terminal repeats (LTRs). The entire nucleotide sequence of the LTR and adjacent cellular sequences at the 5' end of a cloned integrated proviral DNA obtained from BALB/Mo mouse has been determined. It was compared to the nucleotide sequence of the LTR at the 3' end. The results indicate: (i) a direct 517-nucleotide repeat at the 5' and 3' termini; (ii) 145 nucleotides out of 517 nucleotides represent sequences between the 5'-CAP nucleotide and 3' end of the primer tRNA (strong-stop DNA); (iii) an 11-nucleotide inverted repeat is present at the ends of the 5'-LTR and a total of 17 out of 21 nucleotides at the termini are inverted repeats; (iv) sequences CAATAAAAG (at positions -24 to -31) and CAATAAAC (at positions +46 to +53) resembling the hypothetical
DNA-dependent RNA polymerase
II promoter site can be identified in the 5'-LTR; (v) the sequence GAAA appears to be repeated on both sides of the junction of viral and cellular sequences; and (vi) in analogy with the bacterial transposons, the presence of an inverted repeat sequence at the termini of 5'-LTR suggests that M-MLV also has the integration properties of a transposon.
...
PMID:Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. 625 55
We have investigated the ability of molecularly cloned murine type C retroviral DNA to direct accurate initiation of RNA synthesis when added to cell-free extracts. Two different cloned proviruses were used. The first was derived from an integrated molecule of AKR murine
leukemia
virus and contains adjacent host information. The origin of the second was an unintegrated permuted copy of Harvey murine sarcoma virus. We found that the
leukemia
virus cloned provirus, as predicted by structural considerations, contained two functional
RNA polymerase II
promoters located in the U3 region present at either end of the molecule. These promoters initiate transcription at equal rates in vitro. We also found that the permuted sarcoma virus clone contained an
RNA polymerase II
promoter in the U3 region. Removal of viral sequences 49 bases upstream of the in vitro sarcoma virus initiation site by restriction cleavage results in loss of specific transcription, indicating a role for this information in in vitro promotion. The 5' ends of in vitro and in vivo viral RNA were compared by nuclease mapping techniques and found to be identical. Based on this evidence, we conclude that murine retroviral genomes contain sufficient information to initiate transcription independent of any host information in vitro and that these viral promoters are probably also active in vivo. In addition to the promoter in U3, Harvey murine sarcoma virus contains a second promoter in vitro that initiates near the 5' boundary of the transformation-specific (src) region of the virus. Initiation by this promoter was insensitive to low levels of alpha-amanitin, and the RNA transcript could be terminated to yield a 340-nucleotide product.
...
PMID:Specific transcriptional initiation in vitro on murine type C retrovirus promoters. 627 Jun 79
Biochemical studies on a new antitumor antibiotic, CI-920, have been directed toward understanding its mode of action. The most striking effect brought on by CI-920 was a marked inhibition of macromolecular synthesis. L1210
leukemia
cells exposed to 10 microM CI-920 exhibited a decreased rate of DNA, RNA, and protein synthesis within 45 min, and maximal inhibition occurred within 60 min. The reduction in nucleic acid synthesis was not due to precursor depletion, since ribonucleoside and deoxyribonucleoside triphosphate levels in cells exposed to 10 microM CI-920 for 2 h either remained unchanged relative to control cells or were elevated, suggesting a block more directly at the level of nucleotide incorporation. Nevertheless, CI-920 (50 microM) had no effect on DNA or
RNA polymerase
activity as assessed in permeabilized L1210 cells. However, if viable cells were exposed to 20 microM CI-920 for 1 h prior to permeabilization and then the polymerases assayed in the absence of drug, there was a 60% depression in enzyme activity. The inhibition of
RNA polymerase
appears to result from an effect on the enzyme rather than the template, since inhibition of
RNA polymerase
activity in cell-free systems from drug-treated cells could not be restored by addition of excess DNA template. DNA polymerase, however, was at least partially restored by addition of template and therefore was inconclusive in this respect. The data, then, suggest that CI-920 inhibits nucleic acid synthesis directly at the level of nucleotide incorporation, either by direct inhibition of DNA or
RNA polymerase
or by inactivation of an essential component of these enzyme systems. Since the drug in its parent form did not inhibit nucleic acid synthesis in cell-free systems the effects may possibly be mediated through conversion of this agent to another chemical form within viable cells.
...
PMID:Studies on the biochemical mechanism of the novel antitumor agent, CI-920. 654 19
A mutant of Moloney murine
leukemia
virus (M-MuLV), pMOV-psi-, was constructed by deletion of about 350 nucleotides from an infectious proviral DNA clone between the putative env mRNA 5' splice site and the AUG that initiates the coding sequence for Pr65gag. Although the parent wild-type proviral clone, pMOV-psi+, quickly causes a high level of reverse-
transcriptase
-containing virus particles to be released from transfected NIH/3T3 cells, transfection of pMOV-psi- into these cells initially results in very little release. By 9 to 10 days after transfection, however, pMOV-psi- -transfected cells produce infectious virus. Thus pMOV-psi- has a defect that can be repaired in transfected NIH/3T3 cells, presumably by recombination with a sequence normally present in the cells. Cell lines with pMOV-psi- stably integrated into chromosomal DNA produce reverse-
transcriptase
-containing particles that lack detectable M-MuLV RNA but the cells efficiently complement replication-defective, packagable retroviruses. Thus pMOV-psi- has a defect in the packaging of genomic RNA into virions but can provide in trans the products necessary for virion production. The deletion in pMOV-psi- appears to define a site required in cis for packaging of MuLV RNA into virions. Cell lines carrying pMOV-psi- can be used to produce helper-free stocks of natural or synthetic defective retroviruses.
...
PMID:Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. 667 8
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>